Part D Plans With Most Enrollees Getting Deeper Discounts In ’07 – Astra Exec
Executive Summary
The Medicare Part D prescription drug plans that enrolled the largest number of beneficiaries in 2006 have generally been able to extract deeper discounts from manufacturers in the second year of the drug benefit, AstraZeneca U.S. CEO Tony Zook said in an interview with "The Pink Sheet."
You may also be interested in...
Medicare price negotiation
AstraZeneca "remains a strong supporter of the private sector approach embodied in the [Medicare Modernization Act] and does not support legislation granting HHS negotiating authority" the company says, clarifying Medicare-related comments in a recent article (1"The Pink Sheet" Feb. 26, 2007, p. 15)...
Medicare price negotiation
AstraZeneca "remains a strong supporter of the private sector approach embodied in the [Medicare Modernization Act] and does not support legislation granting HHS negotiating authority" the company says, clarifying Medicare-related comments in a recent article (1"The Pink Sheet" Feb. 26, 2007, p. 15)...
Financial Analysts Roundtable: Medicare Part D, Big Pharma Diversification And The Outlook For M&A
Three large cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the outlook for the drug industry in 2007. Below are excerpts from a conversation with Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. In the second part of the series, slated to appear in the Feb. 12 issue, the analysts discuss the impact of the changes on Capitol Hill and the regulatory climate.